title: Elimination of islet cell antibodies and glutamic acid decarboxylase antibodies II in a patient with newly diagnosed insulin-dependent diabetes mellitus.
abstract: Islet cell antibodies and glutamic acid decarboxylase II (GAD II) antibodies have been discussed in the autoimmune pathogenesis of insulin-dependent diabetes mellitus (IDDM). Hence, immunosuppressants, intravenous immunoglobulins, and plasmapheresis have been used in an effort to modulate autoimmune activity and thereby prevent the destruction of pancreatic beta-cells. We describe the autoantibody (islet cell antibody and GAD II) kinetics and clinical course in a patient with newly diagnosed IDDM treated with a specific immunoglobulin apheresis technique. Five days after the initial diagnosis a 37-year-old patient with IDDM underwent a series of seven immunoglobulin aphereses. Immunoglobulin (IgG, IgA, IgM), islet cell antibody, GAD II, and C-peptide concentrations were monitored for a time course of 74 days. Daily insulin requirements were recorded. One single immunoglobulin apheresis decreased IgG by 66.2 +/- 9.1%, IgA by 66.8 +/- 8.7%, and IgM by 57.7 +/- 12.9%. GAD II antibodies were reduced by 61.9 +/- 12.4%. The islet cell antibody titer declined from 1:32 to 1:4 after the treatment series. There were no relevant changes in the safety parameters determined nor were there any clinical side effects. The efficient decrease in islet cell antibodies and glutamic acid decarboxylase II antibodies in a patient with IDDM encourages further investigations into the impact of this treatment on the clinical course of this autoimmune disorder.
authors.affiliation: Medical Department II, University of Munich, Germany.
authors.forename: W O
authors.initials: WO
authors.lastname: Richter
authors.forename: M G
authors.initials: MG
authors.lastname: Donner
authors.forename: P
authors.initials: P
authors.lastname: Schwandt
mesh_terms: D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D001323:Autoantibodies / Q000276:immunology; D001781:Blood Component Removal; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000628:therapy; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007515:Islets of Langerhans / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D007136:Immunoglobulins; D005968:Glutamate Decarboxylase